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Tolerogenic dendritic cells (tolDCs) are a promising treatment modality for diseases
caused by a breach in immune tolerance, such as rheumatoid arthritis. Current
medication for these diseases is directed toward symptom suppression but no real
cure is available yet. TolDC-based therapy aims to restore immune tolerance in an
antigen-specific manner. Here we used a mouse model to address two major questions:
(i) is a maturation stimulus needed for tolDC function in vitro and in vivo and is maturation
required for functioning in experimental arthritis and (ii) can tolDCs modulate CD4+
T cell responses? To answer these questions, we compared matured and immature
dexamethasone/vitamin D3-generated tolDCs in vitro. Subsequently, we co-transferred
these tolDCs with naïve or effector CD4+ T cells to study the characteristics of transferred
T cells after 3 days with flow cytometry and Luminex multiplex assays. In addition, we
tested the suppressive capabilities of tolDCs in an experimental arthritis model. We found
that tolDCs cannot only modulate naïve CD4+ T cell responses as shown by fewer
proliferated and activated CD4+ T cells in vivo, but also effector CD4+ T cells. In addition,
Treg (CD4+CD25+FoxP3+) expansions were seen in the proliferating cell population in
the presence of tolDCs. Furthermore, we show that administered tolDCs are capable
to inhibit arthritis in the proteoglycan-induced arthritis model. However, a maturation
stimulus is needed for tolDCs to manifest this tolerizing function in an inflammatory
environment. Our data will be instrumental for optimization of future tolDC therapies for
autoimmune diseases.
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INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation in
the joints which causes cartilage and bone destruction (1). To date, there is no cure available
and treatment is directed toward mitigating symptoms (non-steroidal anti-inflammatory drugs) or
dampening the immune response (disease modifying anti-rheumatic drugs) (2, 3). These therapies
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suppress the immune system non-specifically and thus are not
completely effective and have side effects. RA, as other chronic
inflammatory diseases, is caused by a disbalance in the immune
system. Immune tolerance for self-antigens is not maintained
which means that autoreactive T cells can attack the body’s
own cells.
Regulatory T cells (Tregs), mainly CD4+ T cells, are able
to restore immune tolerance by suppressing effector cells in an
antigen-specific manner. In patients with autoimmune disease, it
is thought that a subtle change in function or presence of Tregs
is involved in the pathogenesis of the disease. However, a lot
of controversy exists in this area. Several studies show that the
suppressive capacities of Tregs in synovial fluid of RA patients
are diminished, while in peripheral blood these capacities are
maintained (4–6). Other studies indicate a decrease in Treg
numbers (7, 8), which could cause excessive inflammation in
RA. Antigen specific Tregs are able to suppress this excessive
inflammation by suppressing the immune cells that cause the
pathological autoimmune response while leaving protective
immunity intact.
As a tool to induce antigen specific Tregs, tolerogenic
dendritic cells (tolDCs) can be used. TolDCs are dendritic
cells (DCs) that are modulated to become immune tolerance-
inducing. Whether a DC is immune stimulatory or immune
tolerant mainly depends on the environmental cues the DCs
receive determines if they become immunogenic or tolerogenic.
By modulating DCs in vitro, they can be steered toward an
immune tolerant status. Multiple approaches for inducing a
tolerogenic function in antigen presenting cells in vitro have
been described (9–12). We focus on dexamethasone and 1α,25-
dihydroxyvitamin D3 modulated DCs (13–15) because this type
of tolDCs has recently been tested in a phase I clinical trial in
inflammatory arthritis patients (16).
The advantage of tolDCs is that they can be loaded with
an antigen to specifically target autoreactive T cells without
affecting other immune responses. We have shown previously
that loading tolDCs with disease specific-antigen enhances
their efficiency compared to non-loaded tolDCs (17). Some
groups show therapeutic effects with non-loaded tolDCs (18),
but generating non-specific Tregs may give rise to general
immune suppression thereby increasing the risk of infections.
Furthermore, administering non-loaded tolDCs might not
actively induce Tregs but generate T cell anergy, which in turn
can suppress excessive Th17 and Th1 responses (19). Since the
autoantigen that causes disease in RA is currently unknown,
non-loaded tolDC treatment could be an option.
In addition to the issue of antigen loading, the stability
of a tolDC is an important issue to address. Since DCs are
essential for both tolerance and immunity they are the sentinels
of the immune system. It is plausible that non-stimulated
tolDC change their phenotype when entering an immune
stimulatory environment. Therefore, partial maturation with
lipopolysaccharide (LPS) (15, 20), monophosphoryl Lipid A
(MPLA, lipid A portion of LPS) (21) or a cytokine cocktail (22)
would be preferable. This potentially stabilizes the phenotype of
the tolDC and improves antigen presentation and migration (9,
15). A more complete understanding of the working mechanism
of tolDCs will contribute to the development of tolDC treatment
in the future. For that reason, we aimed to (i) determine
the role of maturation in murine dexamethasone and 1α,25-
dihydroxyvitamin D3 induced tolDCs and function in arthritis,
and (ii) study the effects of tolDCs on CD4+ T cell responses.
MATERIALS AND METHODS
Mice
Female Balb/cAnNCrl of 18–20 weeks old were purchased from
Charles River laboratories for in vivo arthritis experiments. Male
Balb/cAnNCrl of 10 weeks old were purchased from Charles
River laboratories for co-transfer studies. hPG TCR transgenic
(23) mice were bred at the central animal laboratory of Utrecht
University, the Netherlands. Both sexes were used as donor
mice. Animals were kept under standard conditions of the
animal facility and all experiments were approved by the Animal
Experiment Committee of Utrecht University (project number
AVD108002016467). Mice were randomly divided in control- or
treatment groups and all animals were monitored and scored
three times a week during the arthritis experiments.
BMDC Culture
Bone marrow was isolated from the femur and tibia from
Balb/cAnNCrl (both male and female) 10–20 weeks old mice
and seeded 450.000 fresh cells/ml in 6 wells plates (Corning
costar). As culture medium IMDM (Gibco) supplemented
with 10% FCS (Bodinco), 100 units/ml penicillin, 100µg/ml
streptomycin and 5 × 10−5 M β-mercaptoethanol in the
presence of 20 ng/ml GM-CSF (in house produced) was used.
On day 2 an equal volume of fresh culture medium containing
20 ng/mL GM-CSF was added, and on day 4/5 20 ng/mL fresh
GM-CSF was supplemented to the culture. Tolerogenicity was
induced by adding 10−6M dexamethasone (Invivogen) and
10−10M 1α,25-dihydroxyvitamin D3 (Enzo Life sciences) to the
BMDC culture on day 7. Simultaneously with the tolerogenic
agents, 10µg/mL peptide (hPG: ATEGRVRVNSAYQDK) and
maturation stimuli (lipopolysaccharide (LPS) 10 ng/mL; Sigma
Aldrich or Monophosphoryl Lipid A (MPLA, 10 ng/mL) from
Salmonella minnesota R595; Invivogen) were added. After 8
days of culture at 37◦C, 5% CO2, the BMDCs or tolDCs
were harvested for further experimentation. Before co-culture,
BMDCs or tolDCs were replated into 24 wells plates (Corning
costar). Before injection in co-transfer experiments, BMDCs or
tolDCs were thoroughly washed with medium (2x) and PBS (1x)
and kept on ice.
Co-cultures
For co-culture experiments, spleens frommB29b TCR transgenic
mice were pooled and CD4+ cells were isolated using Dynal bead
isolation (Invitrogen) by negatively selecting CD4+ T cells with
a mixture of the following in house produced antibodies: anti-
B220 (RA3-6B2), anti-CD11b (M1/70), anti-MHC-II (M5/114)
and anti-CD8 (YTS169). To gain a naïve population, CD25+ and
CD44+ cells were depleted by adding an anti-CD25 antibody
(PC61, produced in house from hybridoma ATCC PC61 and
purified from supernatants) and an anti-CD44 antibody (IM7.8,
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kindly provided by Tibor Glant) in predetermined optimal
concentrations. The purified naïve CD4+ T cells were added to
BMDCs in a 10:1 ratio.
Flow Cytometry and Antibodies
Flow cytometry was performed with FACS Canto II (BD) with
monoclonal antibodies CD4-V500 (RM4-5, BD Biosciences),
CD25-PerCP-Cy5.5 (PC61.5, eBioscience/Thermofisher),
Thy1.1-PerCP-Cy5.5 (HIS51, eBioscience/Thermofisher),
FoxP3-eFluor450 (FJK-16s, eBioscience/Thermofisher), CD62L-
PE (MEL-14, BD biosciences), NKp46-PE-Cy7 (29A1.4,
eBioscience/Thermofisher) and CD3-APC (145-2C11, BD
biosciences). Red blood cells were lysed with ACK (Ammonium-
Chloride-Potassium) buffer. For BMDC phenotyping the
following monoclonal antibodies were used: I-A/I-E Horizon450
(M5/114.15.2, eBioscience/Thermofisher), CD11c APC (N418,
eBioscience/Thermofisher), CD86 FITC (GL1, BD biosciences),
PD-L1 PE (10F.9G2, Biolegend), IL12p40/70 PE (C15.6, BD
biosciences). To identify dead cells the Zombie NIR fixable
viability kit (Biolegend) was used.
Induction of PGIA
Human proteoglycan (hPG) was isolated from human articular
cartilage as described (24). To induce arthritis, Balb/c mice were
injected twice intraperitoneally with a mixture of 2mg DDA and
250µg human proteoglycan with a 21 day interval. Subsequently,
mice were randomized among experimental groups, and arthritis
scores were determined in a blinded fashion using a visual scoring
system based on swelling and redness of paws as described (24).
tolDCs (1× 106 cells in 200 µL PBS) were injected intravenously
on day 17.
Co-transfers
Naïve CD4+ T Cell Co-transfer
CD4+CD25−CD44− T cells were purified from spleens of
hPG TCR transgenic Thy1.1+ mice by Dynal bead isolation
(Invitrogen). A representative dot plot of the transferred
cells is shown in Supplementary Figure 1A. The purified
naïve CD4+ T cells (23) were labeled with 0.5µM 5,6-
carboxyfluorescein-succinimidyl-ester (CFSE, Invitrogen) and
subsequently intravenously injected (max 10 x 106) in 200µl PBS
in acceptor mice (8–10 weeks old male Balb/cAnNCrl) (day 0).
On day one, 1 × 106 freshly cultured hPG pulsed BMDCs or
tolDCs were intravenously injected in the same acceptor mice.
After 3 days, spleens from acceptor mice were harvested and
transferred CD4+ T cells were tested for proliferation, activation
and phenotype. A schematic prestation of the experiments is
depicted in Figure 1.
Activated CD4+ T Cell Co-transfer
On day −3 the donor hPG TCR transgenic Thy1.1+ mice were
intra muscularly (left quadriceps) injected with 100 µg hPG
peptide in 50 µl PBS (Figure 1). On day 0, CD4+ T cells
were purified from spleens from hPG TCR transgenic Thy1.1+
mice (23) by Dynal bead isolation (Invitrogen). Representative
dot plot of the transferred cells and the expression of CD44,
CD62L CD25, and FoxP3 are in Supplementary Figure S1B.
The purified CD4+ T cells were labeled with 0.5µM 5,6-
carboxyfluorescein-succinimidyl-ester (CFSE, Invitrogen) and
subsequently intravenously injected in 200 µl PBS in acceptor
mice (8–10 weeks old male Balb/cAnNCrl) (day 0). On day
one, 2 × 105 or 1 × 106 freshly cultured tolDCs (MPLA
stimulated; mtolDC) or BMDCs (LPS matured; mBMDC) were
intravenously injected in the same acceptor mice. Both cell types
(tolDC or BMDC) were either non-loaded or pulsed with hPG.
After 3 days, spleens from acceptor mice were harvested and
transferred CD4+ T cells were tested on proliferation, activation
and phenotype. A schematic prestation of the experiments is
depicted in Figure 1.
Cytokine Analysis
Supernatants of ex vivo stimulations or co-cultures were used
for multiplex cytokine analysis of IL-10, IL-2, IL-6, IL-17, and
IFN-γ using the Magpix (Luminex XMAP) system according
to manufacturer’s instructions. Briefly, supernatant together
with magnetic beads coated with capture antibodies for the
respective cytokines were added to polystyrene, black, 96 wells
flat bottom plates (Greiner bio-one, 655096). Subsequently,
biotin-conjugated detection antibodies and Streptavidin-PE (BD
Bioscience) were added and incubated together. The antibody
pairs used:
The concentrations of cytokines in the tested samples were
calculated using standard curves of recombinant proteins and
the MFI data was analyzed using a 5-parameter logistic method
(xPONENT software, Luminex, Austin, USA).
ELISpot
Multiscreen IP filter plate plates (Milipore) were activated
with 70% Ethanol and coated with a rat anti-mouse anti-
IFN-γ antibody (clone AN-18, in house produced) or anti-
IL-10 antibody (JES5-2A5, in house produced) at 2µg/ml in
PBS and then blocked with IMDM medium supplemented
with 5% FCS. Subsequently, single cell suspensions of spleen
from co-transferred acceptor mice were cultured in 200 µl
complete medium for 48 h in 96-wells flat bottom plates
for ELISPOT (Millipore) at 5 × 106 cells/ml. Medium or
20µg/ml hPG peptide were added as restimulation. After
culture, the plates were washed and the IFN-γ or IL-10
producing cells were detected using the rat anti-mouse biotin-
anti-IFN-γ antibody (clone XMG1.2, BD biosciences) or rat anti-
mouse biotin-anti-IL-10 antibody (clone SXC-1, BD biosciences),
respectively. Streptavidin-alkaline phosphatase (Sigma, S2890)
and BCIP/NPT solution (Roche) were used to visualize the spots
according to manufacturer’s instructions. Counting of the IFN-
γ or IL-10 producing cells was done by the Automated ELISpot
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FIGURE 1 | Schematic representation of the co-transfer experiments. Activated hPG Thy1.1+ TCR transgenic CD4+ T cells where isolated either fromTCR Tg mice
that were immunized with hPG i.m. at day −3. Naïve CD4+Thy1.1+ T cells where isolated from untreated and depleted of CD25+ and CD44+ CD4+ T cells prior to
transfer to naïve balb/c mice at day 0. One day after T cell transfer mice received and i.v. injection with (tol)DC as described and after 3 days spleens where isolated
for further analysis.
Assay Video Analysis System (A.EL.VIS GmbH). To calculate the
relative increase (stimulation index: SI), the negative (medium)
control was set to 1. The stimulated conditions (hPG or αCD3)
were calculated relative to the control: (hPG/αCD3 sample x 1)/
negative control.
Statistical Analyses
The following statistical analyses were performed using Prism
7.04: repeated measures analysis of variance (ANOVA) with
Dunnett or Bonferroni correction for comparisons between
multiple groups, paired Student t-test for comparisons between
two groups.
RESULTS
Peptide Pulsed tolDCs Show a
Semi-mature Phenotype and Hamper
CD4+ T Cell Activation in vitro
First, we investigated the change in phenotype of tolDCs after
stimulation with a TLR4 agonist in vitro. DCs were generated
from bone marrow and treated with dexamethasone and the
active form of vitamin D3 to develop tolDCs. Untreated bone
marrow derived dendritic cells (BMDCs) were used as controls.
To compare the phenotype of BMDCs and tolDCs, both cell
types were measured unstimulated (immature BMDCs; iBMDCs
or immature tolDCs; itolDCs) or after stimulation with the
lipid A portion of LPS: MPLA (mature BMDCs; mBMDCs
or mature tolDCs; mtolDCs). TolDCs were stimulated with
MPLA since TLR4 stimulation might be required for antigen-
processing and migration. Considering that LPS cannot be used
in humans, we usedMPLA. Both itolDCs andmtolDCs exhibited
a semi-mature phenotype, consisting of a lower expression
of MHC-II, CD86 (Figures 2A,B) and a higher PD-L1/CD86
ratio compared to their respective control BMDCs (iBMDCs
or mBMDCs). The PD-L1/CD86 ratio is considered indicative
of a tolerogenic phenotype as described in multiple studies
(20, 25, 26) Furthermore, MPLA stimulation of tolDCs did not
induce a proinflammatory cytokine profile as shown by the trend
toward a higher IL-10 production and lower IL-12 and IL-6
(Figure 2C) which is important since cytokine signaling is one
of the mechanisms of DCs to communicate. To study their
function, peptide pulsed itolDCs or mtolDCs were co-cultured
with naïve CD4+ T cells from a TCR transgenicmouse (27). After
3 days of co-culture with itolDCs or mtolDCs, fewer CD4+ T
cells expressed the activation marker CD25. Additionally, more
CD4+ T cells expressed CD62L compared to the controls. Next to
this, there was a trend toward more CD4+FoxP3+ cells after co-
culturing with tolDCs (Figure 2D, Supplementary Figure S2).
To correct for inter experimental variance in FoxP3% data have
been normalized and represented as ratio compared to iBMDC
treated mice. CD4+ T cells that were in co-culture with non-
peptide pulsed itolDCs or mtolDCs did not show any activation
or proliferation since these CD4+ T cells are antigen-specific. To
address CD4+ T cell activation and differentiation status their
cytokine profile was analyzed (Figure 2E). TolDCs impair pro-
inflammatory cytokine production of the CD4+ T cells by 2–20
fold compared to CD4+ T cells stimulated by control BMDC.
In addition the anti-inflammatory cytokine IL-10 production
was not diminished shifting the cytokine balance/profile toward
a tolerogenic profile in co-culture with tolDCs, indicating that
these T cells contain a more regulatory character. Thus, tolDCs
modulate CD4+ T cell activation and drives them toward an
immune tolerant state. In these experiments, maturation of the
tolDCs did not influence their effect on CD4+ T cells.
TolDCs Restrict the Activation of Naïve
Antigen Specific CD4+ T Cells in vivo
To determine if tolDCs can affect naïve CD4+ T cells in vivo we
performed co-transfer experiments. First, we transferred naïve
hPG-TCR Thy1.1+ transgenic CD4+ T cells and subsequently (1
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FIGURE 2 | TolDCs exhibit a semi-mature phenotype and remain stable after challenge in vitro. TolDCs were generated by adding dexamethasone and
1,25-dihydroxyvitamin D3 and stimulated with MPLA or medium as control. Phenotype was measured by flow cytometry. In the histogram, mBMDCs (black line),
(Continued)
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FIGURE 2 | itolDCs (blue) and mtolDCs (green) representatives are shown (A). The ratio to immature BMDC was used to determine the difference in expression of
MHC-II, CD86 and PD-L1 in the CD11c+ population. The ratio was used for MHC-II and CD86 because of the inter-experimental variance. iBMDCs were set to 1 and
mBMDC and tolDCs were compared to these cells (B). Cytokine production (C) was measured in the supernatant by Magpix (IL-10, IL-6) or intracellular by flow
cytometry (IL-12p70). iBMDCs, mBMDCs, itolDCs or mtolDCs were pulsed with peptide and co-cultured for three days with naïve (CD25+ and CD44+ depleted)
CD4+ T cells. On day 3, phenotype of the CD4+ T cells was determined by flow cytometry (D). For CD25+FoxP3, the ratio (in CD4+ population) to CD4+ T cells that
were in co-culture with BMDCs was used to compare the difference when co-culturing with tolDCs. The ratio was used because of the inter-experimental variance.
The respective control BMDC-T cell co-cultures were set to 1 and tolDC co-cultured T cells were compared to BMDC co-cultured T cells. As markers for activation
status of the CD4+ T cell, CD25 and CD62L were measured. Cytokine production was measured after co-culture in the supernatant by Magpix (E). Data shown are
mean ± SEM. Two-tailed paired student T-test was used. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. N = 4.
day later) itolDCs or mtolDCs pulsed with hPG peptide into a
naïve acceptor mouse. By transferring CD4+ T cells that contain
a congenic marker (Thy1.1), we were able to select only the
transferred CD4+ T cells for analysis ex vivo. As a control, LPS
matured BMDCs (mBMDCs) instead of tolDCs loaded with
hPG peptide were transferred with naïve CD4+ T cells. Nearly
100% of the CD4+ Thy1.1+ T cells that were co-transferred with
mBMDCs proliferated, while the CD4+Thy1.1+ T cells that were
co-transferred with itolDCs ormtolDCs proliferated, respectively
45 and 75% (Figures 3A,B). At the same time, the CD25
expression was lower on the hPG TCR transgenic CD4+Thy1.1+
T cells that were co-transferred with itolDCs. Furthermore, the
antigen specific CD4+ Thy1.1+ T cells that were in the presence
of itolDCs or mtolDCs showed a lower CD62L expression
compared to the control (Figure 3B). This indicates that next
to in vitro modulation, both immature and mature tolDC can
also modulate the CD4+ T cell response in vivo. The percentage
CD4+FoxP3+ in the total CD4+Thy1.1+ transferred cells was
not significantly increased when tolDCs were co-transferred.
However, in the presence of itolDCs, we observed a trend toward
a higher percentage CD4+FoxP3+ cells in the proliferating
population (Figure 3C and Supplementary Figure S3).
To further define the phenotype of the CD4+ T cells ex
vivo, IL-10 and IFN-γ secreting cells were measured by ELISpot.
The amount of IL-10 producing antigen specific CD4+ T cells
was similar when itolDCs, mtolDCs, or mBMDCs were present
in vivo, and although not significantly visually the amount of
IFN-γ producing cells tended to be lower when mice were co-
transferred with itolDCs or mtolDCs (as shown by the decreasing
trend in Figure 3D). These results confirm that CD4+ T cell
activation is constrained after encountering tolDCs in vivo.
TolDCs Are Capable of Modifying Effector
CD4+ T Cells
Since tolDCs are intended to be used as therapeutic agents
under inflammatory conditions, restraining the activation of
naïve CD4+ T cells alone may not be sufficient. In addition,
tolDCs should also be able to diminish responses of activated
T cells. Therefore, we performed co-transfer studies with a
mixture of (both memory and effector) activated CD4+ T cells to
investigate if tolDCs are capable to modify such proinflammatory
T cells. We co-transferred itolDC, mtolDC or mBMDC pulsed
with peptide and activated peptide-specific CD4+Thy1.1+ T cells
into a naïve acceptor Balb/c mouse. Both itolDCs and mtolDCs
inhibited further proliferation and activation of the peptide-
specific CD4+Thy1.1+ T cells in vivo (Figure 4A), similar as
was seen when naïve CD4+Thy1.1+ T cells were injected.
Next to this, in mice that were injected with tolDCs, not only
more Tregs (CD4+CD25+FoxP3+) were measured (Figure 4B,
Supplementary Figure S4), but these CD4+CD25+FoxP3+ cells
were also more activated as shown by an increase in CD44
expression when compared to mice that received mBMDCs
(Figure 4B). In addition, the spleens of mice which received
tolDCs contained more naïve CD4+Thy1.1+ T cells 3 days after
co-transfer as shown by an increase in CD62L positive cells and a
decrease in CD25 (Figure 4A) and CD44 (data not shown). These
results indicate that tolDCs are not only able to modulate naïve
CD4+ T cells but also previously activated CD4+ T cells in vivo.
Mice in which activated CD4+ T cells were co-transferred with
itolDC, mtolDC or mBMDC pulsed with an irrelevant peptide
did not show any proliferation or activation of the peptide-
specific CD4+ T cells, showing that these are antigen dependent
(data not shown).
TolDCs Ameliorate Proteoglycan Induced
Arthritis
To study if tolDCs are able to affect arthritic symptoms, we
performed in vivo arthritis studies in the proteoglycan induced
arthritis (PGIA) model. Female Balb/c mice were injected with
hPG protein and dimethyl-dioctadecylammonium (DDA) two
times intraperitoneal with a 3-week interval to induce arthritis.
Non-loaded tolDCs or tolDCs loaded with hPG peptide were
injected intravenously on day 17 in the pre-clinical phase of
disease. As pre-clinical phase is considered the stage in which the
mice received the first immunization with hPG protein andDDA.
In these 2 weeks before the second hPG/DDA injection, the mice
develop antibodies against hPG but do not experience symptoms
yet (28). This is comparable to humans in whom autoantibodies
can be detected years before symptoms occur. Mice treated with
itolDCs showed equal arthritis scores compared to the PBS mice
(Figure 5A). However, treatment with non-loaded mtolDCs as
well as mtolDCs loaded with hPG resulted in a reduced and
delayed development of arthritis (Figure 5B). No significant
difference was observed between mice that were injected with
non-loaded mtolDCs or mtolDCs loaded with hPG peptide.
These results indicate that a maturation stimulus is needed for
tolDCs to be effective in vivo. Taking the day of onset and
maximum arthritis score into account (Table 1, data combined
from two independent in vivo studies), the mice that were treated
with mtolDCs not only show less arthritis but develop symptoms
at a later time point than PBS mice.
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FIGURE 3 | tolDCs restrict the activation of naïve antigen specific CD4+ T cell in vivo. (Im)mature tolDCs or mature BMDCs were pulsed with hPG peptide and
transferred (1 × 106 cells/ injection) 1 day after the naïve CFSE labeled hPG TCR transgenic CD4+ T cells. Proliferation (A,B) and phenotype (B,C) from the
(Continued)
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FIGURE 3 | transferred CD4+Thy1.1+ T cells was measured by flow cytometry. To further examine the activation status of the transferred CD4+ Thy1.1+ T cells,
splenocytes were stimulated with hPG (antigen specific) or soluble αCD3 (general). After 3 days, IFNγ and IL-10 producing cells were measured by ELISpot (D). Data
shown are mean ± SEM. Each dot represents an individual mouse. Data are from three independent experiments. One way ANOVA (Dunnett) was used. *p ≤ 0.05,
***p ≤ 0.001, ****p ≤ 0.0001.
FIGURE 4 | tolDC pulsed with peptide inhibit further activation of CD4+ T cells in vivo. First, hPG TCR transgenic CD4+Thy1.1+ T cells were activated in vivo by
injecting hPG peptide i.m. into the transgenic mice. After 3 days, CD4+ Thy1.1+ TCR transgenic T cells were isolated and transferred into a naïve Balb/c acceptor
mouse. One day later, hPG pulsed itolDC, mtolDC or mBMDCs were injected into the acceptor mice. After 3 days, phenotype and proliferation of the transferred
CD4+ Thy1.1+ T cells was measured by flow cytometry in spleen (A,B). Data shown are mean ± SEM. Each dot represents an individual mouse. One way ANOVA
(Dunnett) was used. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.
Ex vivo analyses of spleen and draining lymph nodes (popliteal
lymph nodes) show that Tregs (defined as CD4+CD25+FoxP3+
cells) are present in lower quantities in the spleen (Figure 5C)
in mtolDC treated mice as compared to PBS mice (controls).
However, in the popliteal lymph node there are more
CD4+CD25+FoxP3+ cells present only in mice that received
antigen-pulsed mtolDCs compared to PBS mice (Figure 5C,
Supplementary Figure S5). The arthritis experiments described
show that tolDC treatment can be effective if tolDCs are
stimulated with MPLA prior to infusion.
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FIGURE 5 | hPG loaded or non-loaded tolDCs matured with MPLA ameliorate PGIA. Arthritis was induced by injecting the mice two times (day 0 and day 21) with
hPG protein and DDA. TolDCs (1 × 106 cells in 200 µL PBS) were administered intravenously on day 17, before the second hPG/DDA injection. Mice were scored
three times a week for arthritis. The arthritis scores are based on a visual scoring system. Mice received either PBS, immature tolDCs (itolDC) (A) or mtolDCs
(B) non-loaded or pulsed with disease specific antigen (hPG). Data shown in A and B are from one in vivo experiment. PBS: n = 6, mtolDCs no ag: n = 5, mtolDCs +
hPG: n = 7 (C) The percentage CD4+CD25+FoxP3+ (Treg) was analyzed ex vivo in the spleen and popliteal lymph nodes by flow cytometry. Data shown are mean ±
SEM. Each dot represents an individual mouse. Two way ANOVA (Dunnett) was used to compare all three groups in an unbiased fashion. *p ≤ 0.05, ****p ≤ 0.0001.
TABLE 1 | MtolDCs ameliorate PGIA and delay the onset of disease.
Group Day of onset Maximum
arthritis score
Total number of
mice (n)
PBS 35.36 ± 8.0 5.82 ± 3.52 14
mtolDCs (no ag) 41.27 ± 7.45 3.36 ± 3.44 11
mtolDCs + hPG 41.85 ± 7.49 3.269 ± 2.48 13
MtolDCs reduce arthritis scores (maximum arthritis scores) and delay the onset of PGIA
(day of onset) when compared to the PBS mice. As day of onset is considered the
first day that a mouse has a score of 1. Two-tailed paired student T-test was used, no
significant differences.
Matured tolDCs Are Able to Take Up
Antigen in vivo
We observed in the arthritis experiments (Figure 5) that non-
loaded mtolDCs are also able to lower arthritic symptoms. To
investigate if this was due to general immunosuppressive factors
(e.g. cytokines) or antigen dependent, we performed a co-transfer
experiment in which we tested if mtolDCs are able to take up
hPG in vivo. Therefore, hPG TCR transgenic CD4+Thy.1.1+ T
cells were injected into an acceptor mice followed 1 day later by
an intramuscular injection with hPG peptide and an intravenous
injection with mtolDCs or mBMDCs. To study if non-pulsed
mtolDCs could internalize hPG in vivo, we included a condition
in which the acceptor mice received no DC injection but only the
hPG TCR transgenic CD4+Thy1.1+ T cells.
The mice that received no intravenous (tol)DC injection
show 3–5% CD4+ T cells that proliferated adequately (Figure 6).
This is most likely proliferation induced by APCs from the
recipient mouse presenting hPG. The mice that were injected
with non-loaded mtolDCs (“mtolDCs no ag” in Figure 6) show
5–22% proliferating CD4+ T cells. This indicates that the non-
pulsed mtolDCs indeed are able to take up hPG in vivo and
actively presented it to CD4+ T cells. The mice treated with
hPG loaded mBMDCs and mtolDCs show similar responses as
in Figures 2, 3.
DISCUSSION
TolDCs are potentially useful for inducing immune tolerance
in RA. In this study we addressed two questions: (i) is
tolDC maturation required for their function in vitro
and in vivo, and (ii) can tolDCs modulate CD4+ T cell
responses. TolDCs are able to hamper activation and
proliferation of naïve and effector CD4+ T cells in vitro
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FIGURE 6 | Non-loaded mtolDCs take up hPG in vivo. First, CD4+ TCR
transgenic T cells were isolated and transferred into a naïve Balb/c acceptor
mouse 1 day later, hPG peptide was injected i.m into the acceptor mouse
followed by i.v. injection of non-loaded mtolDCs or hPG pulsed mtolDCs or
mBMDC. After 3 days, proliferation of the transferred CD4+ T cells was
measured by flow cytometry). To minimize background of spontaneous
proliferation, cells that have divided more than 3 times (>3x) were analyzed.
Data shown are mean ± SEM. Each dot represents an individual mouse. N =
3 per group. One way ANOVA (Dunnett) was used. **p ≤ 0.01, ***p ≤ 0.001.
or under immune homeostatic circumstances. However,
tolDC maturation is required under inflammatory conditions
to inhibit arthritis.
Since maturation of tolDCs induces metabolic changes in the
DC which might be necessary for stabilization, cell survival and
function of tolDCs (9, 15, 29), we tested both non-stimulated
and MPLA stimulated tolDCs. Furthermore, we also tested
LPS stimulated tolDCs on phenotype and functionality
which gave similar results to MPLA stimulated tolDC
(Supplementary Figure S6). In addition, mtolDC phenotype
remained stable even in the presence of a pro-inflammatory
cytokine mix consisting of IL-1β, GM-CSF, IL-6, TNF, and IFNγ
in vitro (data not shown).
As shown in Figure 5, tolDCs need stimulation with MPLA
to exert their function in the arthritis model. However, itolDCs
were also efficient in modulating the CD4+ T cell response in the
co-transfer studies. We hypothesize that this difference is caused
by the proinflammatory milieu in the arthritis experiments,
which is not present in the in vivo co-transfer experiments.
itolDCs are able to modulate CD4+ T cells in these “neutral”
environments, but when a proinflammatory milieu is present
they are not potent enough to induce tolerance and/or disease
suppressing responses or cannot reach the inflammatory sites due
to a lack of migration.
To answer the second question, if tolDCs can modulate
CD4+ T cells, we investigated how tolDCs influence CD4+
T cells to adopt a tolerant phenotype. As shown in the co-
transfer studies, tolDCs abrogated not only the activation and
proliferation of naïve CD4+ T cells (Figure 3) but also inhibited
further activation of pre-activated CD4+ T cells (Figure 4).
Next to effects on CD4+ T cell activation, we have shown
that tolDCs also affect CD4+CD25+FoxP3+ cells (Tregs). The
observation locally enhanced numbers of CD25+FoxP3+ are
present (Figure 5C) can imply that Tregs migrate to the site of
inflammation under the influence of mtolDCs, however intrinsic
differences in Treg homeostasis in the different lymphoid
organs cannot be excluded (30). Furthermore, the co-transfer
studies indicate that tolDCs have the potential to activate
Tregs (Figure 4).
Currently, there is still a lot of debate about antigen loading of
tolDCs. In our experiments antigen loading did not significantly
enhance the efficacy of treatment. Both the non-loaded mtolDC
as the hPG loaded mtolDC injections caused reduced and
delayed arthritis symptoms in the treated mice (31). However,
this antigen-independence might be evoked by the fact that the
mtolDCs were administered before the second injection with
hPG/DDA. A possible explanation that the non-loaded mtolDCs
reduced arthritis, is that they took up hPG in vivo since by
injecting hPG/DDA a depot is formed thereby inhibiting arthritis
in an antigen-specific manner. This hypothesis is supported by
the data shown in figure 6. In addition, preliminary studies
have shown that if we add supernatant from cultured tolDCs to
antigen presenting cells in the presence of CD4+ T cells in vitro,
the proliferation of the CD4+ T cells is abrogated (unpublished
observations), indicating that the tolDCs exert their function, at
least partly, via soluble mediators (e.g., cytokines).
In conclusion, tolDCs abrogate activation and proliferation
of both naïve as pre-activated CD4+ T cells and potentially
activate Tregs. Although itolDCs are effective under immune
homeostasis, maturation of the tolDCs is needed to inhibit
experimental arthritis.
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